Jacquelyn Turcinovic

Dr. Jacquelyn Turcinovic

Virology, Immunology, and Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Cell Reports
Verified
Journal Article
Open access
DKDevin J. Kenney
Devin J. Kenney
AOAoife K. O’cOnnell
Aoife K. O’cOnnell
Jacquelyn TurcinovicJacquelyn Turcinovic
Jacquelyn Turcinovic
PMPaige Montanaro
Paige Montanaro
RHRyan M. Hekman
Ryan M. Hekman
Florian DouamFlorian Douam
Florian Douam
The human immunological mechanisms defining the clinical outcome of SARS-CoV-2 infection remain elusive. This knowledge gap is mostly driven by the lack of appropriate experimental platforms recapitulating human immune responses in a controlled human lung environment. Here, we report a mouse model (i.e., HNFL mice) co-engrafted with human fetal lung xenografts (fLX) and a myeloid-enhanced human immune system to identify cellular and molecular correlates of lung protection during SARS-CoV-2 infection. Unlike mice solely engrafted with human fLX, HNFL mice are protected against infection, severe inflammation, and histopathological phenotypes. Lung tissue protection from infection and severe histopathology associates with macrophage infiltration and differentiation and the upregulation of a macrophage-enriched signature composed of 11 specific genes mainly associated with the type I interferon signaling pathway. Our work highlights the HNFL model as a transformative platform to investigate, in controlled experimental settings, human myeloid immune mechanisms governing lung tissue protection during SARS-CoV-2 infection.

10 April 2023 in iScience
Verified
Journal Article
Open access
PDF file
DCDa-Yuan Chen
Da-Yuan Chen
Jacquelyn TurcinovicJacquelyn Turcinovic
Jacquelyn Turcinovic
SFShuchen Feng
Shuchen Feng
DKDevin J. Kenney
Devin J. Kenney
CCChue Vin Chin
Chue Vin Chin
MSMohsan Saeed
Mohsan Saeed
• Human cell lines overexpressing ACE2 and TMPRSS2 were tested for SARS-CoV-2 infection • Two cell lines, Caco-2 and HuH-6, exhibited remarkable susceptibility to infection • Caco-2 and HuH-6 cells allowed isolation of SARS-CoV-2 from clinical specimens • Caco-2 cells supported production of genetically stable recombinant SARS-CoV-2

4 February 2022 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Adam HumeAdam Hume
Adam Hume
BHBaylee Heiden
Baylee Heiden
JOJudith Olejnik
Judith Olejnik
ESEllen L. Suder
Ellen L. Suder
SRStephen Ross
Stephen Ross
Elke MühlbergerElke Mühlberger
Elke Mühlberger
Next generation sequencing has revealed the presence of numerous RNA viruses in animal reservoir hosts, including many closely related to known human pathogens. Despite their zoonotic potential, most of these viruses remain understudied due to not yet being cultured. While reverse genetic systems can facilitate virus rescue, this is often hindered by missing viral genome ends. A prime example is Lloviu virus (LLOV), an uncultured filovirus that is closely related to the highly pathogenic Ebola virus. Using minigenome systems, we complemented the missing LLOV genomic ends and identified cis-acting elements required for LLOV replication that were lacking in the published sequence. We leveraged these data to generate recombinant full-length LLOV clones and rescue infectious virus. Similar to other filoviruses, recombinant LLOV (rLLOV) forms filamentous virions and induces the formation of characteristic inclusions in the cytoplasm of the infected cells, as shown by electron microscopy. Known target cells of Ebola virus, including macrophages and hepatocytes, are permissive to rLLOV infection, suggesting that humans could be potential hosts. However, inflammatory responses in human macrophages, a hallmark of Ebola virus disease, are not induced by rLLOV. Additional tropism testing identified pneumocytes as capable of robust rLLOV and Ebola virus infection. We also used rLLOV to test antivirals targeting multiple facets of the replication cycle. Rescue of uncultured viruses of pathogenic concern represents a valuable tool in our arsenal for pandemic preparedness.

3 August 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LCLisa A. Cosimi
Lisa A. Cosimi
CKChristina Kelly
Christina Kelly
SESamantha Esposito
Samantha Esposito
SSScott Seitz
Scott Seitz
Jacquelyn TurcinovicJacquelyn Turcinovic
Jacquelyn Turcinovic
DHDeborah Hung
Deborah Hung
Current US Centers for Disease Control and Prevention COVID-19 guidance for nonimmunocompromised individuals allows ending isolation after 5 days if the individual is asymptomatic or afebrile with improving symptoms.1 Culturable virus, currently the best proxy for transmissibility, is reported after day 5.2 It has been proposed that rapid antigen tests (RATs) might assist in determining isolation periods. However, while RATs correlate with culture positivity during early infection,3,4 there are minimal data after day 5, when persistent RAT positivity has been reported.5,6 We sought to compare rates of RAT positivity, COVID-19 symptoms, and positive viral culture starting day 6 after a COVID-19 diagnosis.

21 July 2025 in The Lancet Microbe
Verified
Journal Article
Open access
JVJoseline M Velasquez-Reyes
Joseline M Velasquez-Reyes
BSBeau Schaeffer
Beau Schaeffer
SCScott R Curry
Scott R Curry
VOVictoria Overbeck
Victoria Overbeck
CSCole Sher-Jan
Cole Sher-Jan
WHWilliam P Hanage
William P Hanage
People who are immunocompromised can develop persistent SARS-CoV-2 infections. Several viral mutations accumulated during the course of such persistent infections have also been observed in prominent variants of concern (VOCs). Here, we characterise persistent infection and viral evolution of SARS-CoV-2 lasting more than 750 days in a person with advanced HIV-1 infection. Between March, 2021, and July, 2022, eight clinical specimens were collected from a person living with HIV, neither receiving antiretroviral therapy nor virally suppressed, and presumed to have been initially infected with SARS-CoV-2 in mid-May, 2020. Viral RNA was extracted from each swab and an amplicon-based sequencing approach was used for genomic analysis of SARS-CoV-2. Variable sites were characterised at the consensus and subconsensus levels, and phylogenetic tools were applied to analyse viral evolution. Publicly available SARS-CoV-2 sequences from GenBank were leveraged to contextualise our sequenced samples and identify any potential evidence of transmission. Genomes formed a monophyletic cluster in the B.1 lineage. 68 consensus and 67 subconsensus single nucleotide variants were observed over the course of infection. The intrahost clock rate remained similar to that of the interhost rate in contemporaneous community sequences (6·74 × 10-4 [95% credible interval 5·05 × 10-4 to 8·54 × 10-4] substitutions per site per year vs 6·11 × 10-4 [5·54 × 10-5 to 6·66 × 10-4]). Mutations grouped into two distinct subpopulations present throughout infection. 10 non-synonymous mutations in the spike protein gene were at positions in common with those defining the omicron lineage (BA.1 or BA.2), of which nine were present before November, 2021. Nine of 18 substitutions present throughout infection were rare in online databases, suggesting a lack of long transmission chains descending from this individual. Convergent SARS-CoV-2 evolution, both in and outside the spike protein, observed in this study suggests parallels with the evolutionary process leading to emergence of the omicron VOC. The inferred absence of onward infections might indicate a loss of transmissibility during adaptation to a single host. Our results underscore the importance of appropriate treatment to cure persistent SARS-CoV-2 infections and monitoring them to understand how mutations contribute to viral adaptation. National Institute of General Medical Sciences of the National Institutes of Health, Centers for Disease Control and Prevention, the National Institute of Allergy and Infectious Diseases, MassCPR, and Morris Singer Foundation.

9 January 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
Adam HumeAdam Hume
Adam Hume
JOJudith Olejnik
Judith Olejnik
MWMitchell R. White
Mitchell R. White
JHJessie Huang
Jessie Huang
Jacquelyn TurcinovicJacquelyn Turcinovic
Jacquelyn Turcinovic
Elke MühlbergerElke Mühlberger
Elke Mühlberger
Single-cell RNA sequencing (scRNA-seq) technologies are instrumental to improving our understanding of virus–host interactions in cell culture infection studies and complex biological systems because they allow separating the transcriptional signatures of infected versus non-infected bystander cells. A drawback of using biosafety level (BSL) 4 pathogens is that protocols are typically developed without consideration of virus inactivation during the procedure. To ensure complete inactivation of virus-containing samples for downstream analyses, an adaptation of the workflow is needed. Focusing on a commercially available microfluidic partitioning scRNA-seq platform to prepare samples for scRNA-seq, we tested various chemical and physical components of the platform for their ability to inactivate Nipah virus (NiV), a BSL-4 pathogen that belongs to the group of nonsegmented negative-sense RNA viruses. The only step of the standard protocol that led to NiV inactivation was a 5 min incubation at 85 °C. To comply with the more stringent biosafety requirements for BSL-4-derived samples, we included an additional heat step after cDNA synthesis. This step alone was sufficient to inactivate NiV-containing samples, adding to the necessary inactivation redundancy. Importantly, the additional heat step did not affect sample quality or downstream scRNA-seq results.